David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors.

Fabrice Chouraqui describes Cellarity's platform and how it is being put to use for indications such as sickle cell disease and MASH.

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines.

CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than others.

CEO Natalie Holles describes how learnings from a setback from the company's first asset have resulted in a new program.

Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1.

Mark Valleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once.

Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations.

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.

He describes how Fog is leveraging the way α-helices mediate interactions with other proteins to solve the undruggable problem.

Andy Schwab describes founding 5AM in 2002 and discusses portfolio companies Radionetics, Latigo, TMRW, and Skye Bioscience.

Joseph Panetta introduces the conference and we discuss the state of biotech in California's numerous biotech hubs.

He discusses some of the key theme of the conference including obesity, IgG, ATTR cardiomyopathy, and more.

He describes what made him excited about the company, and why he views diabetic retinopathy as potentially a bigger opportunity than wet AMD

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.

Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as the company's broader platform.

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.

Kevin Parker describes how Cartography has been building an antigen map over previous years.

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.